

Full title: Investigating the relationship between sleep disturbances and white matter hyperintensities in older adults on the Alzheimer's disease spectrum

Running title: The influence of sleep on WMHs

Farooq Kamal^{1,2}, Cassandra Morrison^{3,4}, Mahsa Dadar^{1,2}

¹Department of Psychiatry, McGill University, Montreal, Quebec, H3A 1A1, Canada

²Douglas Mental Health University Institute, Montreal, Quebec, H4H 1R3, Canada

³Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, H3A 2B4, Canada

⁴McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, H3A 2B4, Canada

‡ Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Corresponding authors:

Farooq Kamal, Mahsa Dadar, Douglas Mental Health University Institute, Montreal, Quebec, Canada

email: farooq.kamal@mail.mcgill.ca, mahsa.dadar@mcgill.ca

Abstract

Background: While studies report that sleep disturbance can have negative effects on brain vasculature, its impact on cerebrovascular disease such as white matter hyperintensities (WMHs) in beta-amyloid positive older adults remains unexplored.

Methods: Linear regressions, mixed effects models, and mediation analysis examined the cross-sectional and longitudinal associations between sleep disturbance, cognition, and WMH burden, and cognition in normal controls (NCs), mild cognitive impairment (MCI), and Alzheimer's disease (AD) at baseline and longitudinally.

Results: People with AD reported more sleep disturbance than NC and MCI. AD with sleep disturbance had more WMHs than AD without sleep disturbances. Mediation analysis revealed an effect of regional WMH burden on the relationship between sleep disturbance and future cognition.

Conclusion: These results suggest that WMH burden and sleep disturbance increases from aging to AD. Sleep disturbance decreases cognition through increases in WMH burden. Improved sleep could mitigate the impact of WMH accumulation and cognitive decline.

1 Introduction

Sleep disturbance refers to experiencing difficulties when falling and/or staying asleep throughout the night. Such disturbances may result in daytime fatigue and may also cause other related problems, such as concentration issues, memory loss, irritability, and depression.¹ Sleep disturbances such as insomnia or sleep apnea are a physiological hallmark of increasing age and become more prevalent in people with mild cognitive impairment (MCI) and Alzheimer's disease (AD).²⁻⁵ Sleep disorders observed in people with AD⁶ and MCI⁷ are more severe than healthy older adults. For example, people with AD and MCI tend to experience more disrupted nocturnal sleep, earlier bedtimes, more variable wake up times, and fragmented sleep, compared to healthy older adults.⁶⁻⁸ Sleep disturbances in aging, MCI, and AD have been observed to be related to increased cognitive change, pathology, and risk/progression of AD.²

With respect to cognition, several studies have noted a positive correlation between the severity of sleep disturbance and the severity of cognitive decline in healthy older adults⁹ and individuals with MCI/AD.^{4,5,10,11} These declines are often observed in global cognition and memory.^{10,11} Additionally, sleep disturbances have been thought to be associated with the accumulation of amyloid-beta ($A\beta$)^{4,5} and neurodegeneration.¹² Higher levels of $A\beta$ deposition have been observed in people with more sleep disruptions.^{4,13-15} The presence of $A\beta$ is observed in people with AD, and is used as a biomarker to identify individuals who will develop AD.¹⁶ Therefore, the relationship between $A\beta$ and sleep highlights the crucial role that sleep plays in the development of AD-related pathology. Other pathological changes in the brain, such as white matter hyperintensities (WMHs), have also been associated with sleep disturbances. For example, insomnia and short sleep durations are associated with increased WMH burden.¹⁷⁻¹⁹ However, the results examining this relationship have not been consistently reported, with some

studies finding no association between sleep disturbance and WMH burden.^{20,21} WMHs are observed as increased signal during T2-weighted or fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) scans. They are often used as a proxy for cerebrovascular disease, which is a well-established contributor to cognitive decline and dementia.^{22–24} WMHs are associated with increased cognitive decline in healthy older adults^{25–27} and in MCI^{26,28–30} as well as increase risk of conversion to MCI and dementia.³¹

The current research investigating the relationship between sleep and WMHs in aging and dementia has several limitations that may account for conflicting results. Previous research has not yet examined regional WMH differences and sleep disturbance in individuals who are amyloid positive. Healthy older adults and individuals with MCI who are amyloid positive are on the AD trajectory, therefore this difference in diagnostic outcome may influence the relationship between sleep and WMH burden. Most studies have used a total brain WMH approach, which may not capture regional differences specific to sleep disturbances. It is possible that sleep may be associated with WMH accumulation in specific regions, therefore a regional approach would provide insight into the relationship between sleep and regional WMHs. Other findings have reported that posterior WMHs are associated with AD^{32,33} while a widespread accumulation of WMH is associated with vascular dementia.³⁴ Thus, a regional approach may indicate whether sleep disturbances are more strongly associated with AD-related WMH burden or vascular-related WMH burden.

The goal of this study was to examine whether sleep disturbances influence WMH burden in healthy older adults, people with MCI, and AD who were amyloid positive, and whether these sleep disturbances influence global cognition. To our knowledge, this would be the first study to examine the relationship between sleep disturbances and WMH burden and

global cognition in older adults who are amyloid positive. Given that sleep disturbances may be modifiable or treatable in older adults using various intervention techniques (e.g., medications, cognitive-behavioral strategies, and circadian therapies),^{35,36} reducing cognitive decline and pathological brain changes may be mitigated by treating sleep disturbance.

2 Methods

2.1 Alzheimer's Disease Neuroimaging Initiative

The data used for this article were taken from the ADNI database (adni.loni.usc.edu), which was established in 2003 as a public-private venture with Michael W. Weiner, MD as the Principal Investigator. ADNI's primary aim is to determine if serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be utilized to measure the progression of MCI and AD. The research was granted ethical approval from the review boards of all the involved institutions, and written consent was obtained from participants or their study partner. The participants for this study were taken from all the ADNI cohorts (ADNI-1, ADNI-2, ADNI-GO, and ADNI-3).

2.2 Participants

Participant inclusion and exclusion criteria are available at www.adni-info.org. All Participants were included in the study if they were between the ages of 55 and 95 and did not display any signs of depression. Healthy older adults did not exhibit memory decline or impaired global cognition, as assessed by the Wechsler Memory Scale, Mini-Mental Status Examination (MMSE) and Clinical Dementia Rating (CDR). MCI participants had MMSE scores between 24 and 30, CDR scores of 0.5, and abnormal scores on the Wechsler Memory Scale. AD

participants had abnormal memory function on the Wechsler Memory Scale, MMSE scores between 20 and 26, a CDR of 0.5 or 1.0, and met the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association criteria.³⁷

To make sure that the participants in this study were on the AD trajectory, participants were only included if they had evidence of amyloid positivity. PET and CSF values were both used to make this determination. Amyloid positivity was identified based on the following criteria: 1) a standardized uptake value ratio (SUVR) of > 1.11 on AV45 PET³⁸, 2) an SUVR of > 1.2 using Pittsburgh compound-B PET,³⁹ 3) an SUVR of ≥ 1.08 for Florbetaben (FBB) PET,⁴⁰ or 4) a cerebrospinal fluid A β 1-42 ≤ 980 pg/ml as per ADNI recommendations.

Participant sleep scores were also downloaded from the ADNI website. Consistent with previous research, the presence of sleep disturbance was determined by caregiver report on the Neuropsychiatric Inventory (NPI), a brief questionnaire form of the NPI (NPI-Q), or Diagnosis and Symptoms Checklist (ADSXLIST).⁴¹⁻⁴³ The NPI is a caregiver-informant interview that assess behavioral changes including sleep problems. The NPI-sleep questionnaire pertains to recent changes in the patient's sleep behavior. The initial question determines the presence or absence of abnormal sleep changes. In the present study, we focused on questions (from all three questionnaires) that were specifically related to sleep and excluded questions that assessed erratic behavior. That is, we kept questions relating to: difficulties in falling asleep (K1), getting up during the night (K2), awakening the caregiver during night (K4), waking up too early in the morning (K6), and excessive daytime napping (K7). In the ADSXLIST, we extracted information on patient insomnia. As for the NPI, three questions were included asking a caregiver if the patient: awakens during night, arises too early in the morning, or takes excessive

naps during the day. These questions were scored as either zero for the absence and one for the presence of each specific symptom. This approach ensured that we were able to accurately identify and include participants who were experiencing sleep disturbance, while minimizing the inclusion of individuals who may have been experiencing other types of disruption.

A total of 912 participants with amyloid positivity were included in this study [198 healthy controls (NC), 504 MCI, and 210 AD]. Out of the 912 participants, 292 had sleep disturbances (47 NC, 159 MCI, and 86 AD). The groups had the following number of average follow-up time: 1) NC: 4.00 years for no sleep disturbance and 4.49 years with sleep disturbance, 2) MCI: 3.18 years for no sleep disturbance and 3.14 years with sleep disturbance, 3) AD: 1.42 years for no sleep disturbance and 1.45 years with sleep disturbance. Only participants that had at least two follow-up visits were included in the study. To ensure that follow-up time duration did not impact our study findings, the models were repeated with the groups matched based on sleep disturbance and follow-up time (i.e., excluding additional follow-up timepoints from groups that had longer follow-up durations).

2.3 Structural MRI acquisition and processing

All participants underwent MRI scanning using standardized acquisition protocols designed and implemented by ADNI. Further details about the MRI protocols and imaging parameters can be found at <http://adni.loni.usc.edu/methods/mri-tool/mri-analysis/>. MRI data from all participants (baseline and longitudinal) was downloaded from the ADNI public website.

All T1w scans were pre-processed using our standard pipeline which includes: noise reduction, ⁴⁴ intensity inhomogeneity correction, ⁴⁵ and intensity normalization into range [0-

100]. The pre-processed images were then linearly (9 parameters: 3 translation, 3 rotation, and 3 scaling) (Dadar et al., 2018) registered to the MNI-ICBM152-2009c average template.⁴⁷

2.4 WMH measurements

A well-established, validated method for segmenting WMHs in aging and neurodegenerative diseases was used to obtain WMH measurements.⁴⁸ This technique has been used in multi-center studies^{49,50} including the ADNI cohort.³¹ WMHs were automatically segmented using the T1w contrast, in addition to location and intensity features from a library of manually segmented scans (50 ADNI participants that were not part of the study) in combination with a random forest classifier to detect the WMHs in new images.⁴⁸ WMHs were segmented using T1w images (instead of FLAIR and T2w/PD scans) because ADNI1 only acquired T2w/PD images with resolutions of $1 \times 1 \times 3 \text{ mm}^3$, whereas ADNI2/GO acquired only axial FLAIR images with resolutions of $1 \times 1 \times 5 \text{ mm}^3$, and ADNI3 acquired sagittal FLAIR images with resolutions of $1 \times 1 \times 1.2 \text{ mm}^3$. Due to the potential inconsistencies in WMH measurements across the ADNI cohorts, we opted to include consistently acquired T1w images to measure WMH burden. These T1w-based WMH volumes have been previously observed to be very highly correlated with FLAIR and T2w based WMH loads in the ADNI dataset.^{46,51} A visual assessment (performed by M.D.) was conducted to assess the quality of the registrations and WMH segmentations. Cases that did not meet the quality control criteria were removed from the analyses (N = 59). The WMH load was determined as the volume of all voxels identified as WMH in the standard space (in mm^3) and was therefore normalized for head size. Regional and total WMH volumes were calculated based on Hammers Atlas.^{51,52} Analyses were completed separately for frontal, temporal, parietal, occipital, total WMHs. Regional WMH values (i.e., frontal, temporal, parietal,

and occipital) were summed across the right and left hemispheres to obtain one score for each region. To achieve normal distribution, All WMH volumes were log-transformed.

2.5 Global Cognition

The Clinical Dementia Rating – Sum of Boxes (CDR-SB) was included as a measure of global cognitive functioning. This cognitive score was also downloaded from the ADNI website.

2.6 Statistical Analysis

2.6.1 Baseline Assessments

Participant demographic information is presented in Table 1. T-tests and chi-square analyses were performed on the demographic information and corrected for multiple comparisons using Bonferroni correction.

The following linear regression models were used to investigate the impact of sleep differences on total, regional WMH load (frontal, temporal, parietal, occipital, and total) within each diagnostic group at baseline. The models included age, years of education, sex, and APOE4 status, as covariates. The categorical variable of interest was Sleep disturbance (i.e., 0 = no, 1 = yes).

$$\text{Baseline WMH} \sim \text{Age} + \text{Education} + \text{Sex} + \text{APOE4} + \text{Sleep disturbance} \quad (1)$$

2.6.3 Longitudinal Assessments

Longitudinal linear mixed-effects models were used to investigate whether there is an interaction between diagnostic group and sleep status, impacting regional WMH loads (frontal, temporal, parietal, occipital, and total). The models included age, years of education, sex, and APOE4

status as covariates. The categorical variables of interest were Sleep disturbance and its interaction with Diagnosis, based on baseline diagnosis. Participant ID was included as a categorical random effect.

$$WMH \sim Age + Education + Sex + APOE4 + Diagnosis + Sleep\ disturbance + \text{Diagnosis:Sleep\ disturbance} + (1|ID) \quad (2)$$

The following linear mixed effects model was conducted to examine whether sleep disturbance would influence global cognition (i.e., CDR-SB). The models included age, years of education, sex, and APOE4 status as covariates. The categorical variable of interest was Sleep disturbance.

$$CDR-SB \sim Age + Education + Sex + + Diagnosis + Sleep\ disturbance + APOE4 + (1|ID) \quad (3)$$

Finally, we used mediation analysis to test the hypothesis that WMH burden mediates the impact of sleep disturbance on future cognitive decline, including age, sex, years of education, and APOE4 status as covariates. Future cognitive decline was measured as yearly rate of change in CDR-SB scores in participants that had at least 3 longitudinal timepoints. The mediation analysis was performed using the mediation toolbox by Wager et al. (2009) (<https://github.com/canlab/MediationToolbox>). A 95% bootstrap confidence interval based on 10,000 bootstrap samples was used to estimate significance.

All continuous values were z-scored within the population prior to the regression and mediation analyses. All results were corrected for multiple comparisons using false discovery rate (FDR), p-values are reported as raw values with significance then determined by FDR correction.⁵³ All statistical analyses were performed using MATLAB version 2021a. To

complete the baseline analysis, we used function fitlm and for longitudinal assessments we used fitlme.

3 Results

3.1 Demographics and Cognitive Scores

Table 1 presents demographic and clinical information of participants in the study. Differences in demographics are reported for those that survived correction for multiple comparisons. The AD group had more people with sleep disturbance (41%) than both MCI (31%) and NC (24%), and the MCI group had significantly more people with sleep disturbance than NC. NCs had significantly greater education levels than AD ($t=3.17$, $p=.001$). NCs had fewer people with APOE $\epsilon 4+$ than both MCI ($\chi^2=28.79$, $p<.001$) and AD ($\chi^2=52.24$, $p<.001$). MCI had more people with APOE $\epsilon 4+$ than AD ($\chi^2=10.81$, $p=.001$). NC had significantly greater body mass index (BMI) than AD ($\chi^2=3.36$, $p<.001$). MCI also had g BMI than AD ($\chi^2=3.50$, $p<.001$). There were no differences in the vascular risk factors of hypertension or diabetes between the groups. Baseline cognitive performance decreased with each stage of progressive decline for the CDRSB (NC:MCI, $t=-35.41$, $p<.001$; NC:AD, $t=-39.75$, $p<.001$; MCI:AD, $t=-24.70$, $p<.001$).

<Insert Table 1 about here>

3.2 Baseline Assessments

Figure 1 shows boxplots of baseline WMHs overall and separately for each lobe. As expected, AD groups had significantly greater WMH burden than the NC group overall and across all regions (t belongs to $[4.56-3.06]$, $p<.01$, Figure 1). MCI had significantly greater WMH burden than the NC group only in the frontal region ($t = 2.15$, $p=.03$). People with AD had significantly greater WMH burden than the MCI group in all regions (t belongs to $[3.46-2.21]$, $p<.03$). In

addition, people with AD who reported sleep disturbance had significantly greater WMH loads at total, frontal, and occipital regions than people with AD without sleep disturbance (t belongs to [2.11–3.12], $p < .03$). No significant differences were observed in MCI and NC groups.

3.3. Longitudinal Assessments

Table 2 summarizes the results of the longitudinal linear mixed effects models, revealing significant interactions between a diagnosis of AD and sleep disturbance. Specifically, people with AD who reported sleep disturbance had significantly increased WMH loads in all regions except occipital compared to both NC (t belongs to [2.58–2.44], $p < .02$) and people with MCI (t belongs to [3.18–2.28], $p < .03$).

<Insert Table 2 about here>

Additional exploratory analyses were completed within the AD group, to investigate whether the longitudinal mixed effects model results (Model 2) remained consistent without contrasting AD patients against NC and MCI. The within-group models also showed significantly greater WMH loads in AD patients with sleep disturbance than AD patients without sleep disturbance in total, frontal, and occipital lobes (t belongs to [2.56–3.99], $p < .01$).

3.3.1. Global Cognition and regional WMH

The longitudinal models showed a significant impact of sleep disturbance on global cognition, as measured by CDR-SB ($t = 2.71$, $p = .007$), suggesting that sleep disturbance (compared to no sleep disturbance) is associated with increased CDRSB scores (i.e., worse cognition). Table 3 summarizes the results of the mediation analyses investigating whether the relationship between sleep disturbance and future cognitive decline is mediated by WMH burden. The results supported the existence of a mediation effect of WMH load on the relationship between sleep

disturbance and future cognitive decline for total, frontal, and occipital WMHs, suggesting that sleep disturbance increases cognitive deficits through increases in WMH burden.

<Insert Table 3 about here>

Discussion

Sleep disturbances are known to increase cognitive decline, AD-related pathology development and risk for AD.² However, the relationship between sleep disturbances and WMHs, a known risk factor of cognitive decline and AD, is relatively unexplored. The current study investigated this association between sleep disturbances and WMHs in amyloid-positive older adults. Furthermore, the impact of sleep disturbances on cognitive functioning was also examined. At baseline, we observed that AD patients with sleep disturbance had significantly larger WMH burden than those without sleep disturbance. Longitudinal results revealed differences between people with AD with sleep disturbance compared to NCs with no sleep disturbance at all regions, except occipital. Furthermore, longitudinal analysis revealed that people with AD with sleep disturbance had increased WMH than MCI. Sleep disturbance was also related to global cognition (as measured by the CDR-SB). Finally, we found a mediation effect of total, frontal, and occipital WMH burden on the relationship between sleep disturbance and future cognition. Taken together, these findings suggest that sleep disturbances are positively associated with WMH accumulation in older adults on the AD trajectory and lead to cognitive deficits through increase in WMH burden.

The results of the current study are consistent with prior research demonstrating a link between sleep disturbance and WMH. Several previous studies with older adults have reported similar results, supporting the notion that sleep disturbances play an important role in WMH

burden.^{17–19} It should be noted that some studies report no association between sleep disturbance and WMH burden.^{20,21} Li et al. (2020) did not specifically investigate the relationship between sleep and WMH but rather focused on the mediating effect of WMH on the relationship between sleep and depression. Therefore, the lack of significant association between sleep and WMH in this study may be due to the use of a sample of older adults with depression, who may have different underlying brain changes than older adults without depression. Additionally, the study did not examine longitudinal data but instead looked at cross-sectional data only. Similarly, Zitser et al. (2020), did not find a significant association between sleep duration and WMH in a large cohort of middle-aged and older individuals over a period of 28 years. However, the study did not examine regional WMH but rather looked at global WMH burden, which may have masked potential regional differences. The authors also noted that their sample had a relatively small proportion of individuals with poor sleep, which may have limited the statistical power to detect significant associations.²¹ Thus, the present study utilizes longitudinal data to provide precise estimates of the association between A β pathology and self-reported sleep duration on WMH burden. This study builds upon smaller baseline studies that have observed this association inconsistently to date.

The results of this study are also consistent with previous reports which found more severe sleep disturbances in people with AD⁶ and MCI⁷ compared to healthy older adults. However, we did not observe a diagnosis by sleep disturbance interaction for MCI (vs healthy older adults), indicating that the relationship between sleep disturbance and WMH burden is not significantly different in people with MCI compared to healthy older adults. On the other hand, we did observe that people with AD with sleep disturbance had increased WMH burden at baseline compared to healthy older adults with and without sleep disturbances. Over time, we

also observed that people with AD had increased WMH compared to both healthy older adults and people with MCI with and without sleep disturbances. These findings follow previous reports indicating that WMH burden is more strongly associated with sleep disturbances in AD.

Sleep disturbance was also observed to be associated with changes in global cognition functioning (as measured by the CDR-SB). This relationship is consistent with previous reports indicating that disturbances in sleep are negatively associated with cognitive functioning.^{10,11} These findings indicate that sleep disturbances are associated with future cognitive decline in older adults on the AD trajectory. Thus, it may be possible to reduce cognitive decline in older adults by managing sleep disturbances. However, it is important to note that future research is needed to examine whether these sleep changes contribute to AD progression or simply reflect early symptoms. In addition, it is possible that different sleep disturbances (e.g., including sleep fragmentation, abnormal sleep duration, insomnia, excessive daytime sleepiness, sleep-disordered breathing), are associated with varying risks of pathological changes and may influence AD in different manners. Previous conflicting findings regarding the association of sleep with WMHs could be attributed to an inconsistent definition of sleep disturbance as well as subjective reports of sleep disturbance. For instance, research examining sleep disturbance typically incorporates a wide range of day and night-time abnormalities from self-reported sleep characteristics. This limitation could lead to the inclusion of individuals who do not actually experience sleep disturbance in the sleep disturbance group, which would contribute to the conflicting findings reported in the literature.

In conclusion, sleep disturbances increase in prevalence in individuals who experience cognitive decline, particularly in AD. These sleep disturbances are associated with decreased quality of life for both patients and caregivers. There is also growing evidence that sleep

disturbances may be linked to A β accumulation and increased atrophy. The current study added to this literature by observing that sleep disturbances are associated with WMH burden in older adults on the AD trajectory. This finding suggests that individuals on the AD trajectory, who experience faster WMH progression,³⁰ may also develop a more widespread accumulation of WMH if they experience sleep disturbances. Therefore, if sleep disturbances are managed, it may be possible to reduce the WMH burden observed in people with AD (in particular for frontal WMHs which have a more vascular origin),⁵⁴ thus reducing cognitive change and slowing disease progression. Identifying and treating sleep disturbances in individuals with dementia may have important implications for disease management and may help develop new interventions to help mitigate disease progression.

References

1. Medic G, Wille M, Hemels MEH. Short- and long-term health consequences of sleep disruption. *Nat Sci Sleep*. 2017;9:151-161. doi:10.2147/NSS.S134864
2. Mander BA, Winer JR, Jagust WJ, Walker MP. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? *Trends Neurosci*. 2016;39(8):552-566. doi:10.1016/j.tins.2016.05.002
3. Lim ASP, Kowgier M, Yu L, Buchman AS, Bennett DA. Sleep fragmentation and the risk of incident Alzheimer's disease and cognitive decline in older persons. *Sleep*. 2013;36(7):1027-1032. doi:10.5665/sleep.2802
4. Ju YES, McLeland JS, Toedebusch CD, et al. Sleep quality and preclinical Alzheimer disease. *JAMA Neurol*. 2013;70(5):587-593. doi:10.1001/jamaneurol.2013.2334
5. Ju YES, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology—a bidirectional relationship. *Nat Rev Neurol*. 2014;10(2):115-119. doi:10.1038/nrneurol.2013.269
6. Bombois S, Derambure P, Pasquier F, Monaca C. Sleep disorders in aging and dementia. *J Nutr Heal Aging*. 2010;14(3):212-217. doi:10.1007/s12603-010-0052-7
7. D'Rozario AL, Chapman JL, Phillips CL, et al. Objective measurement of sleep in mild cognitive impairment: A systematic review and meta-analysis. *Sleep Med Rev*. 2020;52:101308. doi:10.1016/j.smr.2020.101308
8. Bliwise DL. Sleep in normal aging and dementia. *Sleep*. 1993;16(1):40-81. doi:10.1093/sleep/16.1.40
9. Dzierzewski JM, Dautovich N, Ravyts S. Sleep and Cognition in Older Adults. *Sleep Med Clin*. 2018;13(1):93-106. doi:10.1016/j.jsmc.2017.09.009
10. da Silva RAPC. Sleep disturbances and mild cognitive impairment: A review. *Sleep Sci*. 2015;8(1):36-41. doi:10.1016/j.slsci.2015.02.001
11. Mecca AP, Michalak HR, McDonald JW, et al. Sleep disturbance and the risk of cognitive decline or clinical conversion in the ADNI cohort. *Dement Geriatr Cogn Disord*. 2018;45(3-4):232-242. doi:10.1159/000488671
12. Zhu B, Dong Y, Xu Z, et al. Sleep disturbance induces neuroinflammation and impairment of learning and memory. *Neurobiol Dis*. 2012;48(3):348-355. doi:10.1016/j.nbd.2012.06.022
13. Huang, Y., Potter R, Sigurdson W, Santacruz A, et al. Effects of Age and Amyloid Deposition on A β Dynamics in the Human Central Nervous System. *Arch Neurol*. 2012;69(1):51-58. doi:10.1001/archneurol.2011.235.Effects
14. Cordone S, Annarumma L, Rossini PM, De Gennaro L. Sleep and β -amyloid deposition in Alzheimer disease: Insights on mechanisms and possible innovative treatments. *Front Pharmacol*. 2019;10(JUN):1-12. doi:10.3389/fphar.2019.00695
15. Insel PS, Mohlenhoff BS, Neylan TC, Krystal AD, Mackin RS. Association of Sleep and β -Amyloid Pathology among Older Cognitively Unimpaired Adults. *JAMA Netw Open*.

- 2021;4(7):1-12. doi:10.1001/jamanetworkopen.2021.17573
16. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimer's Dement.* 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018
 17. Grumbach P, Opel N, Martin S, et al. Sleep duration is associated with white matter microstructure and cognitive performance in healthy adults. *Hum Brain Mapp.* 2020;41(15):4397-4405. doi:10.1002/hbm.25132
 18. Kocevska D, Tiemeier H, Lysen TS, et al. The prospective association of objectively measured sleep and cerebral white matter microstructure in middle-aged and older persons. *Sleep.* 2019;42(10):1-8. doi:10.1093/sleep/zsz140
 19. Kang JM, Joo SW, Son YD, et al. Low white-matter integrity between the left thalamus and inferior frontal gyrus in patients with insomnia disorder. *J Psychiatry Neurosci.* 2018;43(6):366-374. doi:10.1503/jpn.170195
 20. Li C, Schreiber J, Bittner N, et al. White Matter Microstructure Underlies the Effects of Sleep Quality and Life Stress on Depression Symptomatology in Older Adults. *Front Aging Neurosci.* 2020;12(November):1-11. doi:10.3389/fnagi.2020.578037
 21. Zitser J, Anatürk M, Zsoldos E, et al. Sleep duration over 28 years, cognition, gray matter volume, and white matter microstructure: A prospective cohort study. *Sleep.* 2020;43(5):1-7. doi:10.1093/sleep/zsz290
 22. Van Der Flier WM, Skoog I, Schneider JA, et al. Vascular cognitive impairment. *Nat Rev Dis Prim.* 2018;4(1):1-16.
 23. Abraham HMA, Wolfson L, Moscufo N, Guttmann CRG, Kaplan RF, White WB. Cardiovascular risk factors and small vessel disease of the brain: Blood pressure, white matter lesions, and functional decline in older persons. *J Cereb Blood Flow Metab.* 2016;36(1):132-142. doi:10.1038/jcbfm.2015.121
 24. Tamura Y, Araki A. Diabetes mellitus and white matter hyperintensity. *Geriatr Gerontol Int.* 2015;15:34-42. doi:10.1111/ggi.12666
 25. Bangen KJ, Preis SR, Delano-Wood L, et al. Baseline White Matter Hyperintensities and Hippocampal Volume are Associated with Conversion from Normal Cognition to Mild Cognitive Impairment in the Framingham Offspring Study. *Alzheimer Dis Assoc Disord.* 2018;32(1):50-56. doi:10.1097/WAD.0000000000000215
 26. Kim S, Choi SH, Lee YM, et al. Periventricular white matter hyperintensities and the risk of dementia: A CREDOS study. *Int Psychogeriatrics.* 2015;27(12):2069-2077. doi:10.1017/S1041610215001076
 27. Yoshita M, Fletcher E, Harvey D, et al. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. *Neurology.* 2006;67(12):2192-2198. doi:10.1212/01.wnl.0000249119.95747.1f
 28. Hirao K, Yamashita F, Tsugawa A, et al. Association of White Matter Hyperintensity Progression with Cognitive Decline in Patients with Amnesic Mild Cognitive

- Impairment. *J Alzheimer's Dis.* 2021;80(2):877-883. doi:10.3233/JAD-201451
29. Li JQ, Tan L, Wang HF, et al. Risk factors for predicting progression from mild cognitive impairment to Alzheimer's disease: A systematic review and meta-analysis of cohort studies. *J Neurol Neurosurg Psychiatry.* 2016;87(5):476-484. doi:10.1136/jnnp-2014-310095
 30. Kamal F, Morrison C, Maranzano J, Zeighami Y, Dadar M. Topographical differences in white matter hyperintensity burden and cognition in aging, MCI, and AD. *GeroScience.* Published online 2022:22274087. <http://medrxiv.org/content/early/2022/04/21/2022.04.20.22274087.abstract>
 31. Dadar M, Maranzano J, Ducharme S, Collins DL. White matter in different regions evolves differently during progression to dementia. *Neurobiol Aging.* 2019;76:71-79. doi:10.1016/j.neurobiolaging.2018.12.004
 32. Brickman AM. Contemplating Alzheimer's disease and the contribution of white matter hyperintensities. *Curr Neurol Neurosci Rep.* 2013;13(12). doi:10.1007/s11910-013-0415-7
 33. Habes M, Erus G, Toledo JB, et al. Regional tract-specific white matter hyperintensities are associated with patterns to aging-related brain atrophy via vascular risk factors, but also independently. *Alzheimer's Dement Diagnosis, Assess Dis Monit.* 2018;10:278-284. doi:10.1016/j.dadm.2018.02.002
 34. Bombois S, Debette S, Bruandet A, et al. Vascular subcortical hyperintensities predict conversion to vascular and mixed dementia in MCI patients. *Stroke.* 2008;39(7):2046-2051. doi:10.1161/STROKEAHA.107.505206
 35. Wade AG, Farmer M, Harari G, et al. Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: A 6-month, randomized, placebo-controlled, multicenter trial. *Clin Interv Aging.* 2014;9:947-961. doi:10.2147/CIA.S65625
 36. McCurry SM, Logsdon RG, Teri L, et al. Characteristics of sleep disturbance in community-dwelling Alzheimer's disease patients. *J Geriatr Psychiatry Neurol.* 1999;12(2):53-59. doi:10.1177/089198879901200203
 37. Tierney MC, Fisher RH, Lewis AJ, et al. The NINCDS-ADRDA work group criteria for the clinical diagnosis of probable Alzheimer's disease: A clinicopathologic study of 57 cases. *Neurology.* 1988;38(3):359-364. doi:10.1212/wnl.38.3.359
 38. Landau SM, Lu M, Joshi AD, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β -amyloid. *Ann Neurol.* 2013;74(6):826-836. doi:10.1002/ana.23908
 39. Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: Statistical and pathological evaluation. *Brain.* 2015;138(7):2020-2033. doi:10.1093/brain/awv112
 40. Landau S, Koeppe R, Jagust W. Florbetaben processing and positivity threshold derivation. *Alzheimer's Dis Neuro-imaging Initiat.* Published online 2011.

https://adni.bitbucket.io/reference/docs/UCBERKELEYFBB/UCBerkeley_FBB_Methods_04.11.19.pdf

41. Devanand DP, Lee S, Huey ED, Goldberg TE. Associations between Neuropsychiatric Symptoms and Neuropathological Diagnoses of Alzheimer Disease and Related Dementias. *JAMA Psychiatry*. 2022;79(4):359-367. doi:10.1001/jamapsychiatry.2021.4363
42. Shokouhi S. Associations of informant-based sleep reports with Alzheimer's disease pathologies. *Clin Interv Aging*. 2019;14:1631-1642. doi:10.2147/CIA.S215208
43. Cummings J. The Neuropsychiatric Inventory: Development and Applications. *J Geriatr Psychiatry Neurol*. 2020;33(2):73-84. doi:10.1177/0891988719882102
44. Coupe P, Yger P, Prima S, Hellier P, Kervrann C, Barillot C. An optimized blockwise nonlocal means denoising filter for 3-D magnetic resonance images. *IEEE Trans Med Imaging*. 2008;27(4):425-441. doi:10.1109/TMI.2007.906087
45. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in mri data. *IEEE Trans Med Imaging*. 1998;17(1):87-97. doi:10.1109/42.668698
46. Dadar M, Fonov VS, Collins DL. A comparison of publicly available linear MRI stereotaxic registration techniques. *Neuroimage*. 2018;174(March):191-200. doi:10.1016/j.neuroimage.2018.03.025
47. Fonov V, Evans AC, Botteron K, Almli CR, McKinstry RC, Collins DL. Unbiased average age-appropriate atlases for pediatric studies. *Neuroimage*. 2011;54(1):313-327. doi:10.1016/j.neuroimage.2010.07.033
48. Dadar M, Maranzano J, Misquitta K, et al. Performance comparison of 10 different classification techniques in segmenting white matter hyperintensities in aging. *Neuroimage*. 2017;157(April):233-249. doi:10.1016/j.neuroimage.2017.06.009
49. Anor CJ, Dadar M, Collins DL, Tartaglia MC. The Longitudinal Assessment of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimer's Disease and Their Association With White Matter Hyperintensities in the National Alzheimer's Coordinating Center's Uniform Data Set. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2021;6(1):70-78. doi:10.1016/j.bpsc.2020.03.006
50. Dadar M, Camicioli R, Duchesne S, Collins DL. The temporal relationships between white matter hyperintensities, neurodegeneration, amyloid beta, and cognition. *Alzheimer's Dement Diagnosis, Assess Dis Monit*. 2020;12(1):1-11. doi:10.1002/dad2.12091
51. Dadar M, Maranzano J, Ducharme S, Carmichael OT, Decarli C, Collins DL. Validation of T1w-based segmentations of white matter hyperintensity volumes in large-scale datasets of aging. *Hum Brain Mapp*. 2018;39(3):1093-1107. doi:10.1002/hbm.23894
52. Dadar M, Pascoal TA, Manitsirikul S, et al. Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer's Disease. *IEEE Trans Med Imaging*. 2017;36(8):1758-1768. doi:10.1109/TMI.2017.2693978

53. Benjamini Y, Hochberg Y, Benjamini, Yoav HY. Controlling the False Discovery Rate: A practical and powerful approach to multiple testing. *J R Stat Soc Ser B*. 1995;57(1):289-300. [http://www.stat.purdue.edu/~doerge/BIOINFORM.D/FALL06/Benjamini and Y FDR.pdf](http://www.stat.purdue.edu/~doerge/BIOINFORM.D/FALL06/Benjamini_and_Y_FDR.pdf) http://engr.case.edu/ray_soumya/mlrg/controlling_fdr_benjamini95.pdf
54. McAleese KE, Miah M, Graham S, et al. Frontal white matter lesions in Alzheimer's disease are associated with both small vessel disease and AD-associated cortical pathology. *Acta Neuropathol*. 2021;142(6):937-950. doi:10.1007/s00401-021-02376-2

Figure Legends

Figure 1. Boxplots showing baseline WMH distributions across diagnostic groups for each lobe. NC = normal controls. MCI = Mild cognitive impairment. AD = Alzheimer's Disease. WMH = white matter hyperintensity. SD = Sleep Disturbance. wo = without.

Table 1: Demographic and clinical characteristics for NCs, MCI and AD

Demographic Information	NC n = 198	MCI n = 504	AD n = 210
Baseline Age	75.0 ± 5.2	73.1 ± 7.1	74.4 ± 7.8
Education	16.1 ± 2.6	16.0 ± 2.9 ¹	15.6 ± 2.7 ¹
APOE ϵ 4+	78 (39%)	313 (62%) ¹	158 (75%) ^{1,2}
Sleep Disturbance	47 (24%)	159 (31%) ¹	86 (41%) ^{1,2}
Male sex	91 (46%)	298 (59%) ¹	117 (55%) ¹
BMI	26.5 ± 4.5	26.7 ± 4.7	25.3 ± 4.1 ¹
Hypertension	96 (48%)	238 (47%)	103 (49%)
Diabetes	13 (7%)	36 (7%)	15(7%)
Baseline CDRSB	.04 ± .2	1.55 ± .9 ¹	4.44 ± 1.6 ^{1,2}

Notes: values are expressed as mean ± standard deviation, or number of participants (percentage %). Statistically significant results reported if they survived Bonferroni correction. ¹ = statistically significant difference from NC. ² = statistically significant difference from MCI. BMI = Body Mass Index. APOE ϵ 4+ = number and percentage of people with at least one ϵ 4 allele. NC = normal control. MCI = mild cognitive impairment. AD = Alzheimer's disease.

Table 2: Linear mixed model results showing the interaction between diagnostic group (NC, MCI, and AD) and sleep disturbance.

	Total		Frontal		Temporal		Parietal		Occipital	
	T stat	P	T stat	P	T stat	P	T stat	P	T stat	P
MCI vs NC: Sleep Disturbance	.46	=.654	.12	=.902	.368	.071	.75	.450	-.11	.910
AD vs NC: Sleep Disturbance	2.74	=.006*	2.58	=.009*	2.44	=.015*	2.44	=.01*	.91	.363
AD vs MCI: Sleep Disturbance	2.99	=.003*	3.18	=.001*	2.71	=.006*	2.28	=.02*	1.29	.195

Notes: * Represents results that are significant when uncorrected and bolded values represent those that remained significant after correction for multiple comparisons.

Table 3: Mediation analysis results showing a mediation effect of WMH burden on the relationship between sleep disturbance and future cognition.

	Total		Frontal		Temporal		Parietal		Occipital	
	<i>mean</i>	<i>P</i>	<i>mean</i>	<i>P</i>	<i>mean</i>	<i>P</i>	<i>mean</i>	<i>P</i>	<i>mean</i>	<i>P</i>
a	0.153	0.019	0.176	0.009	0.082	0.230	0.074	0.291	0.189	0.012
b	0.155	<0.001	0.162	<0.001	0.123	<0.001	0.123	0.001	0.104	0.003
c	0.172	0.018	0.174	0.018	0.173	0.021	0.174	0.022	0.173	0.024
c'	0.148	0.042	0.145	0.054	0.163	0.029	0.165	0.030	0.153	0.047
ab	0.024	0.012	0.028	0.005	0.010	0.009	0.009	0.206	0.019	0.007

Notes: a and b confirm the underlying conditions of the mediation analysis, showing that the mediator variable (i.e., WMH) is significantly related to both independent (a, i.e., sleep disturbance) and dependent (b, i.e., future cognitive decline) variables. ab = average causal mediation effect. c' = average direct effect. c = average indirect effect.

Acknowledgments: Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Conflict of Interest: The authors declare no competing interests.

Funding information: Alzheimer's Disease Neuroimaging Initiative; This research was supported by a grant from the Canadian Institutes of Health Research.

Keywords: Older adults, Mild cognitive impairment, Alzheimer's disease, Cognitive decline, White Matter Hyperintensities, Sleep disturbances, Amyloid positivity

